Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression

Our previous study indicated that colon cancer cells varied in sensitivity to pharmacological farnesoid X receptor (FXR) activation. Herein, we explore the regulatory mechanism of FXR in colorectal cancer (CRC) development and aim to design effective strategies of combined treatment based on the reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Junhui, Yang, Kui, Zheng, Jianbao, Zhao, Pengwei, Xia, Jie, Sun, Xuejun, Zhao, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023572/
https://www.ncbi.nlm.nih.gov/pubmed/35449124
http://dx.doi.org/10.1038/s41419-022-04745-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023572/
https://www.ncbi.nlm.nih.gov/pubmed/35449124
http://dx.doi.org/10.1038/s41419-022-04745-5

Ejemplares similares